Looking Back: Ovarian Cancer in 2017

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, shares his thoughts on exciting developments in the ovarian cancer field from 2017. Three poly (ADP-ribose) polymerase (PARP) inhibitors were recently approved for people who have ovarian cancer which are administered orally, so they are convenient to take, and may be taken for a long time. He believes these drugs have great potential in ovarian cancer treatment.